The Molecular Mechanism of Sensitization to Fas-Mediated Apoptosis by 2-Methoxyestradiol in PC3 Prostate Cancer Cells

Molecular Carcinogenesis

Volumn 39, Issue 1, 2004, Pages 1-9

  Shimada, Keiji ^a   Nakamura, Mitsutoshi ^a   Ishida, Eiwa ^a   Kishi, Munehiro ^a   Matsuyoshi, Syuchi ^a   Konishi, Noboru ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

2 methoxyestradiol; Akt; Apoptosis; FLIP; Nuclear factor B

Indexed keywords

2 METHOXYESTRADIOL; 2 MORPHOLINO 8 PHENYLCHROMONE; 3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; CASPASE; DEATH INDUCING SIGNALING COMPLEX; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FLICE INHIBITORY PROTEIN; I KAPPA B ALPHA; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHOTRANSFERASE INHIBITOR; PROCASPASE 8; PROTEIN KINASE B; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANTIGENS, CD95; APOPTOSIS; ARABIDOPSIS PROTEINS; CARRIER PROTEINS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CHROMONES; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEINS; DRUG RESISTANCE, NEOPLASM; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME ACTIVATION; ENZYME INHIBITORS; ESTRADIOL; FATTY ACID DESATURASES; FLAVONOIDS; GENES, DOMINANT; HUMANS; I-KAPPA B PROTEINS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LUCIFERASES; MALE; MITOGEN-ACTIVATED PROTEIN KINASES; MORPHOLINES; NF-KAPPA B; NITRILES; ORGANIC CHEMICALS; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; SULFONES; TUMOR CELLS, CULTURED;

EID: 0347357848     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/mc.10158     Document Type: Article

References (46)

1. Nagata S, Golstein P. The Fas death factor. Science 1995; 267:1449-1456.
2. Yonehara S. Effects of anti-Fas antibodies on lymphocytes and other organs: Preparation of original and new monoclonal antibodies and amelioration of systemic autoimmune disease. Int Rev Immunol 1999;18:329-345.
3. Krammer PH. CD95's deadly mission in the immune system. Nature 2000;407:789-795.
4. Yonehara S, Ishii A, Yonehara M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-down-regulated with the receptor of tumor necrosis factor. J Exp Med 1989;169:1747-1756.
5. Boldin MP, Goncharov TM, Goltsev YV, Wallach D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell 1996;85:803-815.
6. Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995;81: 505-512.
7. Nagata S. Apoptosis by death factor. Cell 1997;88:355-365.
8. Ashkenazi A, Dixit VM. Death receptors: Signaling and modulation. Science 1998;281:1305-1308.
9. Wallach D, Varfolomeev EE, Malinin NL, et al. Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol 1999;17:331-367.
10. Takeuchi T, Sasaki Y, Ueki T, et al. Modulation of growth and apoptosis response in PC-3 and LNCAP prostate-cancer cell lines by Fas. Int J Cancer 1996;67:709-714.
11. Takayama H, Takakuwa T, Dong Z, et al. Fas gene mutations in prostatic intraepithelial neoplasia and concurrent carcinoma: Analysis of laser capture microdissected specimens. Lab Invest 2001;81:283-288.
12. Hedlund TE, Duke RC, Schleicher MS, Miller GJ. Fas-mediated apoptosis in seven human prostate cancer cell lines: Correlation with tumor stage. Prostate 1998;36:92-101.
13. Shimada K, Nakamura M, Ishida E, et al. Contributions of mitogen-activated protein kinase and nuclear factor kappa B to N-(4-hydroxyphenyl)retinamide-induced apoptosis in prostate cancer cells. Mol Carcinog 2002;35:127-137.
14. MacKeigan JP, Collins TS, Ting JP. MEK inhibition enhances paclitaxel-induced tumor apoptosis. J Biol Chem 2000;275: 38953-38956.
15. Suhara T, Mano T, Oliveira BE, Walsh K. Phosphatidylinositol 3-kinase/ Akt signaling controls endothelial cell sensitivity to Fas-mediated apoptosis via regulation of FLICE-inhibitory protein (FLIP). Circ Res 2001;89:13-19.
16. Huang Y, He Q, Hillman MJ, et al. Sulindac sulfide-induced apoptosis involves death receptor 5 and the caspase 8-dependent pathway in human colon and prostate cancer cells. Cancer Res 2001;61:6918-6924.
17. Suh J, Payvandi F, Edelstein LC, et al. Mechanisms of constitutive NF-kappaB activation in human prostate cancer cells. Prostate 2002;52:183-200.
18. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275:1943-1947.
19. Steck PA, Pershouse MA, Jasser SA, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997;15:356-362.
20. Chen ZJ, Parent L, Maniatis T. Site-specific phosphorylation of IkappaBalpha by a novel ubiquitination-dependent protein kinase activity. Cell 1996;84:853-862.
21. Kumar AP, Garcia GE, Slaga TJ. 2-Methoxyestradiol blocks cell-cycle progression at G(2)/M phase and inhibits growth of human prostate cancer cells. Mol Carcinog 2001;31:111-124.
22. Attalla H, Makela TP, Adlercreutz H, Andersson LC. 2-Methoxyestradiol arrests cells in mitosis without depolymerizing tubulin. Biochem Biophys Res Commun 1996;228: 467-473.
23. Mukhopadhyay T, Roth JA. Induction of apoptosis in human lung cancer cells after wild-type p53 activation by methoxyestradiol. Oncogene 1997;14:379-384.
24. Martinez LA, Yang J, Vazquez ES, et al. p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cells. Carcinogenesis 2002;23:1289-1296.
25. Abreu-Martin MT, Chari A, Palladino AA, et al. Mitogen-activated protein kinase kinase kinase 1 activates androgen receptor-dependent transcription and apoptosis in prostate cancer. Mol Cell Biol 1999;19:5143-5154.
26. Rokhlin OW, Bishop GA, Hostager BS, et al. Fas-mediated apoptosis in human prostatic carcinoma cell lines. Cancer Res 1997;57:1758-1768.
27. Li Y, Sarkar FH. Inhibition of nuclear factor kappaB activation in PC3 cells by genistein is mediated via Akt signaling pathway. Clin Cancer Res 2002;8:2369-2377.
28. Irmler M, Thome M, Hahne M, et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997;388:190-195.
29. Algeciras-Schimnich A, Griffith TS, Lynch DH, Paya CV. Cell cycle-dependent regulation of FLIP levels and susceptibility to Fas-mediated apoptosis. J Immunol 1999;162: 5205-5211.
30. Shimada K, Nakamura M, Ishida E, et al. Phosphorylation of Fas-associated death domain contributes to enhancement of etoposide-induced apoptosis in prostate cancer cells. Jpn J Cancer Res 2002;93:1164-1174.
31. 2-terminal kinase-dependent Fas activation contributes to etoposide-induced apoptosis in p53-mutated prostate cancer cells. Prostate 2003;55:265-280.
32. Kim SJ, Hwang SG, Shin DY, et al. p38 kinase regulates nitric oxide-induced apoptosis of articular chondrocytes by accumulating p53 via NFkappa B-dependent transcription and stabilization by serine 15 phosphorylation. J Biol Chem 2002; 277:33501-33508.
33. Shimada K, Nakamura M, Ishida E, et al. Requirement of c-jun for testosterone-induced sensitization to N-(4-hydroxyphenyl)retinamide-induced apoptosis. Mol Carcinog 2003;36: 115-122.
34. French LE, Hahne M, Viard I, et al. Fas and Fas ligand in embryos and adult mice: Ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J Cell Biol 1996; 133:335-343.
35. Bu S, Blaukat A, Fu X, et al. Mechanisms for 2-methoxyestradiol-induced apoptosis of prostate cancer cells. FEBS Lett 2002;531:141-151.
36. 2/M arrest and apoptosis in prostate cancer. Biochem Biophys Res Commun 2001;285:1259-1266.
37. Srinivasula SM, Ahmad M, Ottilie S, et al. FLAME-1, a novel FADD-like anti-apoptotic molecule that regulates Fas/TNFR1-induced apoptosis. J Biol Chem 1997;272:18542-18545.
38. Hu S, Vincenz C, Ni J, et al. I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1- and CD-95-induced apoptosis. J Biol Chem 1997;272:17255-17257.
39. Chatterjee D, Schmitz I, Krueger A, et al. Induction of apoptosis in 9-nitrocamptothecin-treated DU145 human prostate carcinoma cells correlates with de novo synthesis of CD95 and CD95 ligand and down-regulation of c-FLIP (short). Cancer Res 2001;61:7148-7154.
40. Fulda S, Meyer E, Debatin KM. Metabolic inhibitors sensitize for CD95 (APO-1/Fas)-induced apoptosis by down-regulating Fas-associated death domain-like interleukin 1-converting enzyme inhibitory protein expression. Cancer Res 2000; 60:3947-3956.
41. Ivanov VN, Bhoumik A, Ronai Z. Death receptors and melanoma resistance to apoptosis. Oncogene 2003;22:3152-3161.
42. Varadhachary AS, Peter ME, Perdow SN, et al. Selective up-regulation of phosphatidylinositol 3′-kinase activity in Th2 cells inhibits caspase-8 cleavage at the death-inducing complex: A mechanism for Th2 resistance from Fas-mediated apoptosis. J Immunol 1999;163:4772-4779.
43. Holmstrom TH, Schmitz I, Soderstrom TS, et al. MAPK/ERK signaling in activated T cells inhibits CD95/Fas-mediated apoptosis downstream of DISC assembly. Embo J 2000;19: 5418-5428.
44. Yuan XJ, Whang YE. PTEN sensitizes prostate cancer cells to death receptor-mediated and drug-induced apoptosis through a FADD-dependent pathway. Oncogene 2002;21: 319-327.
45. Baeuerle PA, Baltimore D. NF-kappa B: Ten years after. Cell 1996;87:13-20.
46. Herr I, Debatin KM. Cellular stress response and apoptosis in cancer therapy. Blood 2001;98:2603-2614.